Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

US Becomes 1st Country To Approve Respiratory Syncytial Virus Vaccine

US Becomes 1st Country To Approve Respiratory Syncytial Virus Vaccine

Drugmaker GSK's Arexvy was green-lighted for adults aged 60 and older, with similar shots from other makers including Pfizer and Moderna expected to follow soon.
The United States on Wednesday approved the world's first vaccine for the Respiratory Syncytial Virus (RSV), the culmination of a decades-long hunt to protect vulnerable people from the common illness.

Drugmaker GSK's Arexvy was green-lighted for adults aged 60 and older, with similar shots from other makers including Pfizer and Moderna expected to follow soon.

"Today's approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening," said senior US Food and Drug Administration (FDA) official Peter Marks in a statement.

The decision "marks a turning point in our effort to reduce the significant burden of RSV," added Tony Wood, GSK's chief scientific officer.

RSV is a common virus that normally causes mild, cold-like symptoms, but can be serious for infants and the elderly, as well as those with weak immune systems and underlying conditions.

In severe cases it can cause pneumonia and bronchiolitis, an inflammation of the small airways deep inside the lungs.

According to the US Centers for Disease Control and Prevention, RSV leads to approximately 60,000 to 120,000 hospitalizations and 6,000 to 10,000 deaths among adults 65 years of age and older.

Awareness of the disease has increased in recent years, in part because of the strain it has placed on hospital systems over the last two winters.

Rates of RSV and flu fell during Covid-19 lockdowns, but surged when restrictions were lifted, with young children hit hard.

Pharmaceutical companies have been chasing an RSV vaccine for years. Given recent successful breakthroughs in the sector, analysts predict the market could be worth over $10 billion in the next decade, according to reports.

More vaccines on way

GSK's vaccine contains a "subunit" or part of the virus to help train the immune system should it encounter the real thing.

It was approved based on a study of 25,000 people aged 60 and older that showed a single dose was 83 percent effective against disease caused by RSV, and more than 94 percent effective against severe disease.

Researchers will continue to follow volunteers in the study to assess the duration of protection as well as the safety and efficacy of more doses.

The most common side effects included injection site pain, fatigue, muscle pain, headaches and joint stiffness.

An irregular heartbeat was a less common side effect, occurring in 10 participants who received Arexvy and four participants who received placebo.

Safety issues were also found in two other studies of the drug involving approximately 2,500 people aged 60 and up. In one of these studies, two volunteers developed a rare type of inflammation that affects the brain and spinal cord, and one of them died.

In the other study, one participant developed Guillain-Barre syndrome, in which the immune system damages nerve cells, causing muscle weakness and sometimes paralysis.

GSK's Arexvy was recommended for approval last week by the European Union's drug watchdog, the European Medicines Agency, whose positive opinions are normally formally followed by approval from the European Commission.

Pfizer has said that it expects a decision from the FDA in May for its own RSV vaccine, also for those over 60 years old.

In January, Moderna said it hopes its RSV vaccine will be approved and available in time for the Northern Hemisphere's winter later this year.

Several other companies are also developing RSV vaccines.

Last year, the EU approved a preventative antibody treatment against RSV, developed by British-Swedish pharmaceutical firm AstraZeneca and France's Sanofi, which confers temporary protection.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Pope Francis Makes Brief Appearance at Easter Sunday Mass
Saudi Arabia Offers Max Verstappen Unprecedented Deal to Join Aston Martin
Global Pistachio Shortage Amid Rising Demand for 'Dubai Chocolate'
Trump is assembling a coalition of Western leaders aligned with the MAGA vision, strengthening a unified front for global change
IMF Predicts No Global Recession Amid Trade Tensions
Alphabet Faces Antitrust Setbacks as Federal Judges Rule Against Google
US Billionaires Call for Higher Taxes, but Proposed 'Millionaires Tax' May Not Achieve Desired Outcome
This is Vienna, Austria in 2025.
Designed in US, made in China: Why Apple is stuck in tariff tussle
Boeing Jet Returns to US from China Amid Tariff War
US Sets Deadline for Russia-Ukraine Peace Deal Brokerage
Italy Introduces 'Sex Rooms' in Prisons for Inmates
Italian Prime Minister Giorgia Meloni Meets with Donald Trump to Discuss EU-US Trade Tensions
South East Asia Caught in US-China Trade Dispute
Ukraine and US Sign Outline of Minerals Deal
U.S. and Panama Finalize Defense Agreements Amid Canal Access and Chinese Influence Concerns
China Stands Firm Amidst Trade Disputes with the US: A Factual Analysis
U.S. Tariff Escalation Sparks Global Trade Tensions
EU Postpones Retaliatory Measures Against US Tariffs
Alisha Lehmann's Modeling Campaign and Public Controversy Stir Debate Ahead of UEFA Women's Euro
Global Responses to U.S. Tariffs: Varied Reactions from Key Economies
Europe Pursues Digital Autonomy in Light of Transatlantic Strains
OpenAI Secures Unprecedented $40 Billion Funding
Apple's Innovation Divide: Falling Behind in AI and Foldable Technology Amidst Progress from China
Passenger Taken into Custody for Masturbating on SWISS Air Flight
PUTIN’S LIMOUSINE DETONATES—SECURITY CHAOS ENSUES
OpenAI Unveils New Image Generation Tool for ChatGPT
Ex-FIFA President and French Football Icon Acquitted of Corruption Accusations
American Brands Face Consumer Boycott in Europe Amid Escalating Trade and Political Tensions
German President Frank-Walter Steinmeier has just signed off on a national debt hike to fast-track Germany’s militarization
Pope Francis Makes His First Public Appearance in Five Weeks After Being Hospitalized
Pope Francis Released from Hospital Following Pneumonia Treatment
European Countries Boost Defense Budgets Due to Changes in U.S. Support
Pope Francis Set to Leave Hospital Following Recovery from Pneumonia
Thousands Rally in Amsterdam to Oppose Racism and Fascism
Revealing the Electromagnetic Characteristics of the Great Pyramid of Giza
The Development of China's Automobile Sector
Netanyahu Dismisses Shin Bet Chief Amid 'Loss of Trust' and 'Qatargate' Corruption Investigations Involving Netanyahu's Advisors
Leaders of the US and Ukraine Hold Constructive Discussion Amid Ongoing Conflict
EU Charges US Tech Giants with Violating Digital Regulations
Serbia's authoritarian government uses illegal sonic weapons against peaceful demonstrators.
European Union Moves Toward Joint Debt for Military Spending
Mass Protests in Belgrade Against Serbian President and Government
Trump Administration's Deportation of Alleged Gang Members Sparks Legal Dispute
Massive Protests Erupt in Serbia Against President Vučić Amid Corruption Allegations
Large Demonstrations Break Out in Serbia After Fatal Railway Station Collapse
Serbian Government Denies Use of 'Sonic Weapon' Amidst Massive Protests
Serbia Witnesses Unprecedented Protests Following Novi Sad Railway Station Collapse
China Introduces 'Zhulong' C-14 Nuclear Battery Promising a Lifespan of 5,730 Years
Inquiry: Social Media Platforms Permitted Advertisements Featuring Anti-Semitic and Anti-Muslim Material in Germany
×